Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.

Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.

2.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15.

3.

Oncolytic viruses as therapeutic cancer vaccines.

Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS.

Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103. Review.

4.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R.

PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815. Epub 2012 Jan 27.

5.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6. doi: 10.1073/pnas.0803988105. Epub 2008 Sep 24.

6.

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

Edukulla R, Woller N, Mundt B, Knocke S, Gürlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kühnel F, Kubicka S.

Cancer Res. 2009 Feb 15;69(4):1448-58. doi: 10.1158/0008-5472.CAN-08-1160. Epub 2009 Feb 3. Erratum in: Cancer Res. 2011 Mar 1;71(5):2021. Ramakrishna, Edukulla [corrected to Edukulla, Ramakrishna].

7.

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Thorne SH, Liang W, Sampath P, Schmidt T, Sikorski R, Beilhack A, Contag CH.

Mol Ther. 2010 Sep;18(9):1698-705. doi: 10.1038/mt.2010.140. Epub 2010 Jul 6.

8.

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

Park J, Thomas S, Munster PN.

Epigenomics. 2015;7(4):641-52. doi: 10.2217/epi.15.16. Review.

PMID:
26111034
9.

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.

Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T.

Cancer Immunol Immunother. 2013 Apr;62(4):639-52. doi: 10.1007/s00262-012-1366-6. Epub 2012 Nov 11.

10.

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A.

Clin Cancer Res. 2009 Oct 1;15(19):6167-76. doi: 10.1158/1078-0432.CCR-09-0645. Epub 2009 Sep 29.

11.

Oncolytic herpes simplex virus type 1 and host immune responses.

Fukuhara H, Todo T.

Curr Cancer Drug Targets. 2007 Mar;7(2):149-55. Review.

PMID:
17346106
12.

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53.

13.

Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF.

Mol Ther. 2010 Apr;18(4):692-9. doi: 10.1038/mt.2009.318. Epub 2010 Jan 19.

14.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH.

Blood. 2011 Sep 15;118(11):3003-12. doi: 10.1182/blood-2011-02-334565. Epub 2011 Jul 18.

15.

In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts.

Narumi K, Udagawa T, Kondoh A, Kobayashi A, Hara H, Ikarashi Y, Ohnami S, Takeshita F, Ochiya T, Okada T, Yamagishi M, Yoshida T, Aoki K.

Gene Ther. 2012 Jan;19(1):34-48. doi: 10.1038/gt.2011.73. Epub 2011 May 26.

PMID:
21614029
16.

Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.

Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM.

J Immunother. 2004 Jul-Aug;27(4):273-81.

PMID:
15235388
17.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
18.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

19.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

20.

Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors.

Fan R, Wang C, Wang Y, Ren P, Gan P, Ji H, Xia Z, Hu S, Zeng Q, Huang W, Jiang Y, Huang X.

J Transl Med. 2012 May 21;10:101. doi: 10.1186/1479-5876-10-101.

Items per page

Supplemental Content

Write to the Help Desk